UCB S.A.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into UCB's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for UCB over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark UCB's performance against key rivals in the prescription pharmaceutical sector* Examine the long-term sales potential of the monoclonal antibody Cimzia; providing a route to diversify its molecule type and therapy area offering

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
UCB: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
Biopharmaceutical business model key to UCB’s future sales growth
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest comment
Q2 2010
UCB: Vimpat's efficacy in epilepsy confirmed, but other indications offer more commercial potential
Latest prescription pharma product news
Q4 2010
Q3 2010
Q2 2010
Latest corporate news
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Celltech
Schwarz Pharma
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009–14
Core analysis, 2009–15
Expiry analysis, 2009–15
Generics analysis, 2009–15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS AND COMPETITORS
Key findings
Overview
Central nervous system
Keppra/Keppra XR
Rikelta
Neupro
Vimpat
Immunology & inflammation
Cimzia
APPENDIX
References
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]